Glenmark Pharma Gets Usfda Approval For Skin Cream Generic

Glenmark Pharmaceuticals Has Received Final Approval From The Us Health Regulator For Generic Version Of Desonide Cream, Used To Treat A Variety Of Skin Conditions."Glenmark Pharmaceuticals Inc., Usa Has Been Granted Final Approval By The United States Food &Amp; Drug Administration (Us Fda) For Desonide Cream, 0.05 Per Cent, The Generic Version Of Desonide Cream, 0.05 Per Cent Of Perrigo New York Inc," Glenmark Pharmaceuticals Said In A Bse Filing.According To Ims Health Sales Data For The 12 Months To May 2017, Desonide Cream, 0.05 Per Cent, Achieved Annual Sales Of Approximately Usd 44.6 Million, Glenmark Said.The Company'S Current Portfolio Consists Of 120 Products Authorised For Distribution In The Us Marketplace And 65 Abbreviated New Drug Applications (Anda) Pending Approval With The Usfda.Glenmark Pharmaceuticals Shares Were Trading Up By 0.87 Per Cent At Rs 694.90 On The Bse.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!